vs
布林克公司（BCO）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
布林克公司的季度营收约是Revvity的1.8倍（$1.4B vs $772.1M），Revvity净利率更高（12.7% vs 4.9%，领先7.8%），布林克公司同比增速更快（9.1% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs 5.6%）
布林克公司是总部位于美国弗吉尼亚州里士满的现金处理服务企业，业务范围涵盖武装押运、ATM机加钞与维护，还提供金库外包、货币处理、智能保险柜服务、贵重物品国际运输等现金管理与支付相关解决方案。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BCO vs RVTY — 直观对比
营收规模更大
BCO
是对方的1.8倍
$772.1M
营收增速更快
BCO
高出3.2%
5.9%
净利率更高
RVTY
高出7.8%
4.9%
两年增速更快
RVTY
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $772.1M |
| 净利润 | $68.1M | $98.4M |
| 毛利率 | 27.7% | — |
| 营业利润率 | 13.1% | 14.5% |
| 净利率 | 4.9% | 12.7% |
| 营收同比 | 9.1% | 5.9% |
| 净利润同比 | 76.9% | 3.9% |
| 每股收益（稀释后） | $1.62 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCORVTY
| Q4 25 | $1.4B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.3B | $729.4M | ||
| Q3 24 | $1.3B | $684.0M | ||
| Q2 24 | $1.3B | $691.7M | ||
| Q1 24 | $1.2B | $649.9M |
净利润BCORVTY
| Q4 25 | $68.1M | $98.4M | ||
| Q3 25 | $36.3M | $46.7M | ||
| Q2 25 | $43.7M | $53.9M | ||
| Q1 25 | $51.6M | $42.2M | ||
| Q4 24 | $38.5M | $94.6M | ||
| Q3 24 | $28.9M | $94.4M | ||
| Q2 24 | $46.2M | $55.4M | ||
| Q1 24 | $49.3M | $26.0M |
毛利率BCORVTY
| Q4 25 | 27.7% | — | ||
| Q3 25 | 25.8% | 53.6% | ||
| Q2 25 | 24.9% | 54.5% | ||
| Q1 25 | 24.6% | 56.5% | ||
| Q4 24 | 26.1% | — | ||
| Q3 24 | 25.0% | 56.3% | ||
| Q2 24 | 25.2% | 55.7% | ||
| Q1 24 | 25.0% | 54.6% |
营业利润率BCORVTY
| Q4 25 | 13.1% | 14.5% | ||
| Q3 25 | 11.4% | 11.7% | ||
| Q2 25 | 10.3% | 12.6% | ||
| Q1 25 | 9.6% | 10.9% | ||
| Q4 24 | 8.3% | 16.3% | ||
| Q3 24 | 8.9% | 14.3% | ||
| Q2 24 | 9.3% | 12.4% | ||
| Q1 24 | 9.8% | 6.8% |
净利率BCORVTY
| Q4 25 | 4.9% | 12.7% | ||
| Q3 25 | 2.7% | 6.7% | ||
| Q2 25 | 3.4% | 7.5% | ||
| Q1 25 | 4.1% | 6.4% | ||
| Q4 24 | 3.0% | 13.0% | ||
| Q3 24 | 2.3% | 13.8% | ||
| Q2 24 | 3.7% | 8.0% | ||
| Q1 24 | 4.0% | 4.0% |
每股收益（稀释后）BCORVTY
| Q4 25 | $1.62 | $0.86 | ||
| Q3 25 | $0.86 | $0.40 | ||
| Q2 25 | $1.03 | $0.46 | ||
| Q1 25 | $1.18 | $0.35 | ||
| Q4 24 | $0.87 | $0.77 | ||
| Q3 24 | $0.65 | $0.77 | ||
| Q2 24 | $1.02 | $0.45 | ||
| Q1 24 | $1.09 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $919.9M |
| 总债务越低越好 | $4.0B | — |
| 股东权益账面价值 | $277.7M | $7.3B |
| 总资产 | $7.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 14.31× | — |
8季度趋势，按日历期对齐
现金及短期投资BCORVTY
| Q4 25 | $1.7B | $919.9M | ||
| Q3 25 | $1.3B | $931.4M | ||
| Q2 25 | $1.4B | $991.8M | ||
| Q1 25 | $1.2B | $1.1B | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $1.2B | $1.2B | ||
| Q2 24 | $1.2B | $2.0B | ||
| Q1 24 | $1.1B | $1.7B |
总债务BCORVTY
| Q4 25 | $4.0B | — | ||
| Q3 25 | $3.8B | — | ||
| Q2 25 | $3.9B | — | ||
| Q1 25 | $3.7B | — | ||
| Q4 24 | $3.7B | — | ||
| Q3 24 | $3.7B | — | ||
| Q2 24 | $3.6B | — | ||
| Q1 24 | $3.4B | — |
股东权益BCORVTY
| Q4 25 | $277.7M | $7.3B | ||
| Q3 25 | $268.5M | $7.4B | ||
| Q2 25 | $254.6M | $7.6B | ||
| Q1 25 | $205.8M | $7.6B | ||
| Q4 24 | $184.9M | $7.7B | ||
| Q3 24 | $277.1M | $7.9B | ||
| Q2 24 | $320.5M | $7.9B | ||
| Q1 24 | $396.4M | $7.8B |
总资产BCORVTY
| Q4 25 | $7.3B | $12.2B | ||
| Q3 25 | $7.0B | $12.1B | ||
| Q2 25 | $7.1B | $12.4B | ||
| Q1 25 | $6.6B | $12.4B | ||
| Q4 24 | $6.6B | $12.4B | ||
| Q3 24 | $6.7B | $12.8B | ||
| Q2 24 | $6.6B | $13.4B | ||
| Q1 24 | $6.7B | $13.4B |
负债/权益比BCORVTY
| Q4 25 | 14.31× | — | ||
| Q3 25 | 14.05× | — | ||
| Q2 25 | 15.48× | — | ||
| Q1 25 | 18.19× | — | ||
| Q4 24 | 20.26× | — | ||
| Q3 24 | 13.39× | — | ||
| Q2 24 | 11.26× | — | ||
| Q1 24 | 8.67× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | 3.5% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流BCORVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $122.1M | $138.5M | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | $-60.2M | $128.2M | ||
| Q4 24 | $369.8M | $174.2M | ||
| Q3 24 | $58.4M | $147.9M | ||
| Q2 24 | $-66.1M | $158.6M | ||
| Q1 24 | $63.9M | $147.6M |
自由现金流BCORVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $77.4M | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | $-119.1M | $112.2M | ||
| Q4 24 | $307.2M | $149.8M | ||
| Q3 24 | $7.4M | $125.6M | ||
| Q2 24 | $-122.8M | $136.6M | ||
| Q1 24 | $11.7M | $129.7M |
自由现金流率BCORVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | 5.8% | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | -9.6% | 16.9% | ||
| Q4 24 | 24.3% | 20.5% | ||
| Q3 24 | 0.6% | 18.4% | ||
| Q2 24 | -9.8% | 19.7% | ||
| Q1 24 | 0.9% | 20.0% |
资本支出强度BCORVTY
| Q4 25 | 3.5% | 2.6% | ||
| Q3 25 | 3.3% | 2.6% | ||
| Q2 25 | 4.0% | 2.6% | ||
| Q1 25 | 4.7% | 2.4% | ||
| Q4 24 | 5.0% | 3.4% | ||
| Q3 24 | 4.1% | 3.3% | ||
| Q2 24 | 4.5% | 3.2% | ||
| Q1 24 | 4.2% | 2.7% |
现金转化率BCORVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 3.36× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | -1.17× | 3.03× | ||
| Q4 24 | 9.61× | 1.84× | ||
| Q3 24 | 2.02× | 1.57× | ||
| Q2 24 | -1.43× | 2.87× | ||
| Q1 24 | 1.30× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCO
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
